Anturec Pharmaceuticals
Phase 1/2Welcome to ANTUREC, a start-up founded by the Berdel/Schwöppe/Bizimis group. We have developed a therapeutic platform based on the human tissue factor. This fusion protein targets CD13, which is expressed on tumor vascular cells, leading to tumor vascular occlusion and tumor infarction. The lead protein tTF-NGR is currently in clinical phase III in a combination study together with trabectedin against advanced Soft Tissue Sarcomas. Since we target tumor vasculature, the approach is applicable...
About
Welcome to ANTUREC, a start-up founded by the Berdel/Schwöppe/Bizimis group. We have developed a therapeutic platform based on the human tissue factor. This fusion protein targets CD13, which is expressed on tumor vascular cells, leading to tumor vascular occlusion and tumor infarction. The lead protein tTF-NGR is currently in clinical phase III in a combination study together with trabectedin against advanced Soft Tissue Sarcomas. Since we target tumor vasculature, the approach is applicable...
Company Info
Contact
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile